Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,otherAssets,cash,totalCurrentLiabilities,propertyPlantEquipment,totalCurrentAssets,shortTermInvestments,netReceivables,longTermDebt,inventory,accountsPayable,treasuryStock,otherStockholderEquity,otherCurrentAssets,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,changeToInventory,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,exchange,currency,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,marketState,market,shortName,exchangeDataDelayedBy,esgPopulated,tradeable,priceHint,regularMarketChangePercent,regularMarketDayRange,epsTrailingTwelveMonths,epsForward,epsCurrentYear,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Jul 29, 2021) 4","Short Ratio (Jul 29, 2021) 4","Short % of Float (Jul 29, 2021) 4","Short % of Shares Outstanding (Jul 29, 2021) 4","Shares Short (prior month Jun 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,fax,industry,address2
t0,KALA,84270000.0,64642400,3094000,,-36498000,,-36498000,27986000,2035000,-29045000,-29045000,,-2091000,,,,0,3051000,32096000,1016000,-7453000,,-36498000,-36498000,550898000.0,131194000.0,84270000.0,8261000.0,215464000.0,65000.0,-466693000.0,12375000.0,144635000.0,26076000.0,31369000.0,171720000.0,5000000.0,11859000.0,78055000.0,8046000.0,2844000.0,,,,23000000,13000,22674000,1982000,5849000,5779000,6085000,6915000,-21608000,256000,-2578000,347000,-2218000,10706000,-326000,145644000.0,en-US,US,EQUITY,True,Delayed Quote,NMS,USD,3.52,1630526403,0.13999987,3.36,3.61,3.3517,1258147,3.38,0.0,0.0,30,32,finmb_83652421,NasdaqGS,"Kala Pharmaceuticals, Inc.",USD,1770478,1072971,0.8499999,0.318352,2.67 - 9.969,-6.449,-0.6469054,2.67,9.969,1620217800,1620217800,1620217800,PRE,us_market,"Kala Pharmaceuticals, Inc.",0,False,False,4,4.142008,3.3517 - 3.61,-1.958,-0.96,-1.84,-1.9130434,1.721,3.372857,0.14714289,0.043625593,5.800652,-2.280652,-0.39317167,227541248,-3.6666667,2.0453224,15,America/New_York,EDT,-14400000,0.4,,,9.969,2.67,3.3729,5.8007,1.77M,1.07M,64.64M,,42.19M,0.32%,59.88%,8.92M,4.88,18.56%,13.77%,8.53M,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",0.00%,"-1,031.88%",-30.15%,-118.16%,10.78M,0.18,266.30%,4.19M,-110.22M,-125.97M,-1.9580,,149.64M,2.3,107.09M,127.08,6.59,1.72,-105.81M,-57.84M,Value,02472,Healthcare,188,7,7,"Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's product candidates include EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development programs comprise KPI-285/KPI-286, a receptor tyrosine kinase inhibitor program for the treatment of various retinal diseases; SEGRM program, a novel class of compounds designed to regulate gene expression through the transrepression pathway while avoiding the transactivation pathway; and surface targeted steroid program (KPI-333), a new chemical entity as a topical steroid that targets the ocular surface. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Watertown, Massachusetts.",Watertown,781 996 5252,MA,9,1609372800,1625097600,10,United States,http://www.kalarx.com,86400,10,490 Arsenal Way,781 642 0399,Biotechnology,Suite 120
t-1,KALA,109792000.0,64642400,3126000,,-30412000,,-30412000,27699000,2511000,-28314000,-28314000,,-2141000,,,,0,3266000,31580000,755000,-2098000,,-30412000,-30412000,539920000.0,120035000.0,109792000.0,6345000.0,229827000.0,64000.0,-430195000.0,19178000.0,127970000.0,19989000.0,31584000.0,179065000.0,28015000.0,12206000.0,72521000.0,8241000.0,2855000.0,3000.0,3000.0,,48250000,1237000,48031000,-9000,35315000,-3821000,35324000,50706000,-32640000,248000,-2809000,-2602000,-2218000,5241000,-219000,159076000.0,en-US,US,EQUITY,True,Delayed Quote,NMS,USD,3.52,1630526403,0.13999987,3.36,3.61,3.3517,1258147,3.38,0.0,0.0,30,32,finmb_83652421,NasdaqGS,"Kala Pharmaceuticals, Inc.",USD,1770478,1072971,0.8499999,0.318352,2.67 - 9.969,-6.449,-0.6469054,2.67,9.969,1620217800,1620217800,1620217800,PRE,us_market,"Kala Pharmaceuticals, Inc.",0,False,False,4,4.142008,3.3517 - 3.61,-1.958,-0.96,-1.84,-1.9130434,1.721,3.372857,0.14714289,0.043625593,5.800652,-2.280652,-0.39317167,227541248,-3.6666667,2.0453224,15,America/New_York,EDT,-14400000,0.4,,,9.969,2.67,3.3729,5.8007,1.77M,1.07M,64.64M,,42.19M,0.32%,59.88%,8.92M,4.88,18.56%,13.77%,8.53M,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",0.00%,"-1,031.88%",-30.15%,-118.16%,10.78M,0.18,266.30%,4.19M,-110.22M,-125.97M,-1.9580,,149.64M,2.3,107.09M,127.08,6.59,1.72,-105.81M,-57.84M,Value,02472,Healthcare,188,7,7,"Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's product candidates include EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development programs comprise KPI-285/KPI-286, a receptor tyrosine kinase inhibitor program for the treatment of various retinal diseases; SEGRM program, a novel class of compounds designed to regulate gene expression through the transrepression pathway while avoiding the transactivation pathway; and surface targeted steroid program (KPI-333), a new chemical entity as a topical steroid that targets the ocular surface. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Watertown, Massachusetts.",Watertown,781 996 5252,MA,9,1609372800,1625097600,10,United States,http://www.kalarx.com,86400,10,490 Arsenal Way,781 642 0399,Biotechnology,Suite 120
t-2,KALA,99995000.0,64642400,3397000,,-31112000,,-31112000,26466000,1879000,-27984000,-27984000,,-2170000,,,,0,2238000,30222000,359000,-3128000,,-31112000,-31112000,499715000.0,121611000.0,99995000.0,5224000.0,221606000.0,59000.0,-399783000.0,19208000.0,77264000.0,22225000.0,31019000.0,171379000.0,76882000.0,9854000.0,72243000.0,5229000.0,1724000.0,4000.0,4000.0,949000.0,37325000,-592000,36842000,-8000,20722000,3815000,20730000,31645000,-25919000,238000,-945000,-2149000,-2218000,4549000,-483000,149154000.0,en-US,US,EQUITY,True,Delayed Quote,NMS,USD,3.52,1630526403,0.13999987,3.36,3.61,3.3517,1258147,3.38,0.0,0.0,30,32,finmb_83652421,NasdaqGS,"Kala Pharmaceuticals, Inc.",USD,1770478,1072971,0.8499999,0.318352,2.67 - 9.969,-6.449,-0.6469054,2.67,9.969,1620217800,1620217800,1620217800,PRE,us_market,"Kala Pharmaceuticals, Inc.",0,False,False,4,4.142008,3.3517 - 3.61,-1.958,-0.96,-1.84,-1.9130434,1.721,3.372857,0.14714289,0.043625593,5.800652,-2.280652,-0.39317167,227541248,-3.6666667,2.0453224,15,America/New_York,EDT,-14400000,0.4,,,9.969,2.67,3.3729,5.8007,1.77M,1.07M,64.64M,,42.19M,0.32%,59.88%,8.92M,4.88,18.56%,13.77%,8.53M,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",0.00%,"-1,031.88%",-30.15%,-118.16%,10.78M,0.18,266.30%,4.19M,-110.22M,-125.97M,-1.9580,,149.64M,2.3,107.09M,127.08,6.59,1.72,-105.81M,-57.84M,Value,02472,Healthcare,188,7,7,"Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's product candidates include EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development programs comprise KPI-285/KPI-286, a receptor tyrosine kinase inhibitor program for the treatment of various retinal diseases; SEGRM program, a novel class of compounds designed to regulate gene expression through the transrepression pathway while avoiding the transactivation pathway; and surface targeted steroid program (KPI-333), a new chemical entity as a topical steroid that targets the ocular surface. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Watertown, Massachusetts.",Watertown,781 996 5252,MA,9,1609372800,1625097600,10,United States,http://www.kalarx.com,86400,10,490 Arsenal Way,781 642 0399,Biotechnology,Suite 120
t-3,KALA,106030000.0,64642400,3468000,,-27948000,,-27948000,23893000,1519000,-25842000,-25842000,,-2157000,,,,0,2220000,28062000,701000,-2106000,,-27948000,-27948000,474648000.0,119066000.0,106030000.0,6308000.0,225096000.0,56000.0,-368671000.0,15774000.0,45526000.0,19550000.0,31166000.0,178156000.0,113594000.0,7455000.0,71967000.0,7538000.0,2222000.0,-3000.0,-3000.0,,-57057000,641000,-57601000,-8000,746000,5000,754000,-82496000,-25641000,220000,-117000,-3174000,-2218000,4463000,-544000,158606000.0,en-US,US,EQUITY,True,Delayed Quote,NMS,USD,3.52,1630526403,0.13999987,3.36,3.61,3.3517,1258147,3.38,0.0,0.0,30,32,finmb_83652421,NasdaqGS,"Kala Pharmaceuticals, Inc.",USD,1770478,1072971,0.8499999,0.318352,2.67 - 9.969,-6.449,-0.6469054,2.67,9.969,1620217800,1620217800,1620217800,PRE,us_market,"Kala Pharmaceuticals, Inc.",0,False,False,4,4.142008,3.3517 - 3.61,-1.958,-0.96,-1.84,-1.9130434,1.721,3.372857,0.14714289,0.043625593,5.800652,-2.280652,-0.39317167,227541248,-3.6666667,2.0453224,15,America/New_York,EDT,-14400000,0.4,,,9.969,2.67,3.3729,5.8007,1.77M,1.07M,64.64M,,42.19M,0.32%,59.88%,8.92M,4.88,18.56%,13.77%,8.53M,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",0.00%,"-1,031.88%",-30.15%,-118.16%,10.78M,0.18,266.30%,4.19M,-110.22M,-125.97M,-1.9580,,149.64M,2.3,107.09M,127.08,6.59,1.72,-105.81M,-57.84M,Value,02472,Healthcare,188,7,7,"Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's product candidates include EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development programs comprise KPI-285/KPI-286, a receptor tyrosine kinase inhibitor program for the treatment of various retinal diseases; SEGRM program, a novel class of compounds designed to regulate gene expression through the transrepression pathway while avoiding the transactivation pathway; and surface targeted steroid program (KPI-333), a new chemical entity as a topical steroid that targets the ocular surface. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Watertown, Massachusetts.",Watertown,781 996 5252,MA,9,1609372800,1625097600,10,United States,http://www.kalarx.com,86400,10,490 Arsenal Way,781 642 0399,Biotechnology,Suite 120
